Clinical Trials Browser

Phase 2 × Ondansetron × 90 days × Clear all

NCT07381634 2026-03-11

The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular